Compare Plby Group Inc (PLBY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plby Group Inc vs Sana Biotechnology Inc — how do they compare? Plby Group Inc trades at $1.16 (market cap $138.38M), while Sana Biotechnology Inc trades at $3.17 (market cap $947.48M). The key difference: Sana Biotechnology Inc is far larger — about 6.8× Plby Group Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| PLBY | SANA | |
|---|---|---|
Market Cap | $138.38M | $947.48M |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $5.92 |
52-Week Low | $1.11 | $2.68 |
Enterprise Value | $283.96M | $860.73M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLBY trades at $1.18, up 0.85% with a bearish technical signal despite positive cash flow trends. The company shows improving fundamentals with revenue stabilizing around $120M and net losses narrowing significantly from -$278M in 2022 to -$13M in 2025. Recent Q2 2026 earnings beat expectations with a return to operating profitability, while analyst consensus remains strongly bullish with 75% buy ratings.
The outlook suggests cautious optimism as PLBY demonstrates operational turnaround with five consecutive quarters of positive EBITDA. Key risks include high debt levels and negative shareholder equity, but recent share repurchases and Russell index inclusion provide support. The stock faces resistance near current levels with technical indicators signaling caution.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
